D.E. Shaw & Co’s Aspire Biopharma Warrant ASBPW Stock Holding History

D.E. Shaw & Co’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.1K	Hold	199,999	–	–	﹤0.01%	4810
2026 Q1	$3.32K	Hold	199,999	–	–	﹤0.01%	4452
2025 Q4	$3.3K	Hold	199,999	–	–	﹤0.01%	4536
2025 Q3	$5.98K	Hold	199,999	–	–	﹤0.01%	4481
2025 Q2	$8.94K	Hold	199,999	–	–	﹤0.01%	4256
2025 Q1	$13.5K	Hold	199,999	–	–	﹤0.01%	4122
2024 Q4	$9.5K	Hold	199,999	–	–	﹤0.01%	4280
2024 Q3	$8.46K	Hold	199,999	–	–	﹤0.01%	4394
2024 Q2	$6.02K	Hold	199,999	–	–	﹤0.01%	4351
2024 Q1	$6.02K	Hold	199,999	–	–	﹤0.01%	4207
2023 Q4	$12K	Hold	199,999	–	–	﹤0.01%	4107
2023 Q3	$10K	Hold	199,999	–	–	﹤0.01%	4059
2023 Q2	$10K	Hold	199,999	–	–	﹤0.01%	4048
2023 Q1	$8.36K	Hold	199,999	–	–	﹤0.01%	4258
2022 Q4	$16K	Hold	199,999	–	–	﹤0.01%	4553
2022 Q3	$34K	Hold	199,999	–	–	﹤0.01%	4741
2022 Q2	$24K	Buy	+199,999	New	+$43.5K	﹤0.01%	4979

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

D.E. Shaw & Co's ASBPW Position: Q2 2026 in Review

D.E. Shaw & Co held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 199,999 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4810.

D.E. Shaw & Co first reported a position in ASBPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $34K in Q3 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

D.E. Shaw & Co held 199,999 shares of Aspire Biopharma Warrant worth $4.1K as of Q2 2026.
D.E. Shaw & Co left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4810 holding.
D.E. Shaw & Co first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 17 quarters since.
D.E. Shaw & Co's Aspire Biopharma Warrant position peaked at $34K in Q3 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.